What question did this study set out to answer?

To evaluate whether adding postoperative immunotherapy to adjuvant chemotherapy improves disease-free recurrence rates compared with adjuvant chemotherapy alone in patients with radically resected esophageal squamous cell carcinoma.

December 13, 2024Frontiers in MedicineOpen Access

Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates

View Full Paper

Ask AI

Bookmark

Authors

XXXihao XieSouthern Methodist University HZHai ZhangShanghai First Maternity and Infant Hospital HHHaiquan HeFujian Medical University

Discussion

Member takes

Implication

Retrospective study reveals no improvement in two-year recurrence rates with adjuvant immunotherapy in resected esophageal cancer, suggesting limited benefit over chemotherapy alone.

Key Points

To evaluate whether adding postoperative immunotherapy to adjuvant chemotherapy improves disease-free recurrence rates compared with adjuvant chemotherapy alone in patients with radically resected esophageal squamous cell carcinoma.
Retrospective single-center study of 76 patients with pathologically confirmed stage II–IVa esophageal squamous cell carcinoma who underwent radical surgery between January 2020 and August 2022.
Patients received either postoperative adjuvant chemotherapy alone (aCT, n = 40) or postoperative adjuvant immunotherapy combined with chemotherapy (aICT, n = 36).
Assessed adverse events during adjuvant therapy and disease recurrence rates across a 2-year postoperative follow-up period.
The incidence of hypothyroidism during adjuvant treatment was significantly higher in the aICT group than in the aCT group (25.0% vs. 2.5%, p = 0.007).
At 2-year follow-up, local and distant recurrence rates were 13.9% and 5.6% in the aICT group versus 17.5% and 12.5% in the aCT group, demonstrating no statistically significant difference (p = 0.489).

Cite This Study

Xie et al. (2024) studied this question.

synapsesocial.com/papers/6a0cdc388f6db1a225026099 https://doi.org/10.3389/fmed.2024.1517001

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals no improvement in two-year recurrence rates with adjuvant immunotherapy in resected esophageal cancer, suggesting limited benefit over chemotherapy alone.

Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates

Discussion

Member takes

Implication

Key Points

Cite This Study

Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider